Modality
Small Molecule
MOA
ALKi
Target
KRASG12D
Pathway
Proteasome
AngelmanADPKDGBM
Development Pipeline
Preclinical
~Jun 2013
→ ~Sep 2014
Phase 1
~Dec 2014
→ ~Mar 2016
Phase 2
~Jun 2016
→ ~Sep 2017
Phase 3
Dec 2017
→ Jun 2028
Phase 3Current
NCT06360274
289 pts·GBM
2021-03→2026-12·Recruiting
NCT03605023
199 pts·GBM
2018-11→2027-09·Not yet recruiting
NCT04680525
1,629 pts·ADPKD
2025-01→2028-06·Terminated
+1 more trial
4,193 total pts3 indications
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (4)
2026-08-265mo awayPh3 Readout· Angelman
2026-12-128mo awayPh3 Readout· GBM
2027-09-051.4y awayPh3 Readout· GBM
2028-06-232.2y awayPh3 Readout· ADPKD
Trial Timeline
Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3
P3
Not yet…
P3
Not yet…
P3
Recruit…
P3
Termina…
Catalysts
Ph3 Readout
2026-08-26 · 5mo away
Angelman
Ph3 Readout
2026-12-12 · 8mo away
GBM
Ph3 Readout
2027-09-05 · 1.4y away
GBM
Ph3 Readout
2028-06-23 · 2.2y away
ADPKD
RecruitingTerminatedNot yet recruiting|StartCompletionToday
Trials (4)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06360274 | Phase 3 | GBM | Recruiting | 289 | PFS |
| NCT03605023 | Phase 3 | GBM | Not yet recr... | 199 | 6MWD |
| NCT04680525 | Phase 3 | ADPKD | Terminated | 1629 | CfB |
| NCT03002214 | Phase 3 | Angelman | Not yet recr... | 2076 | OS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Miriosocimab | Pfizer | Phase 1 | PARP | |
| Rilulemzoparlimab | Novartis | Phase 2/3 | KRASG12D | |
| MRK-7739 | Merck & Co | Preclinical | IL-23 | |
| BMY-2495 | Bristol-Myers Squibb | Phase 3 | KRASG12D | |
| SNY-2934 | Sanofi | Phase 3 | KRASG12D | |
| Talainavolisib | Novo Nordisk | Preclinical | KRASG12D | |
| DSN-5254 | Daiichi Sankyo | Phase 1 | B7-H3 | |
| Sovacapivasertib | Amgen | Phase 3 | WEE1 | |
| Zanuratamab | Gilead Sciences | Phase 1/2 | CDK2 | |
| GIL-2445 | Gilead Sciences | Phase 2/3 | PSMA |